An Experienced CDMO Can Be A Differentiator In The Rapidly Growing Biologics Market
By Steven Lavezoli, Regional Vice President, Business Development, Scorpius BioManufacturing
The demand for biologic drugs continues to grow at a steady 12–14% annually. To keep up, biotech and biopharma developers are increasingly relying on outsourcing partners to meet both clinical and commercial research, development, and production needs. Contract research, development, and manufacturing organizations like Scorpius BioManufacturing (previously Scorpion Biological Services) that provide end-to-end services, including secure supply chains, can help biologics developers meet accelerated timelines and establish a real competitive advantage in today’s competitive market.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.